Yu JiaDe, Streicher Jenna L, Medne Livija, Krantz Ian D, Yan Albert C
Department of Pediatrics, Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Pediatr Dermatol. 2017 Sep;34(5):e227-e230. doi: 10.1111/pde.13208. Epub 2017 Jul 21.
Capillary malformation-arteriovenous malformation (CM-AVM) syndrome, due to inactivating mutations in RASA1 in 68% of cases, is characterized by the development of cutaneous capillary malformations and arteriovenous malformations or fistulas; no known genetic etiology has been identified in patients with CM-AVM syndrome without RASA1 mutations. We present the case of a child with RASA1-negative CM-AVM syndrome with a de novo missense mutation in EPHB4, a transmembrane tyrosine kinase receptor essential for vasculogenesis. Inactivating the mutation in EPHB4 has been shown to upregulate the mitogen-activated protein kinase pathway and the mammalian target of rapamycin complex 1, possibly contributing to the development of vascular malformations.
毛细血管畸形 - 动静脉畸形(CM - AVM)综合征,68%的病例是由于RASA1基因失活突变所致,其特征为皮肤毛细血管畸形以及动静脉畸形或瘘管的形成;在无RASA1突变的CM - AVM综合征患者中,尚未发现已知的遗传病因。我们报告了一例患有RASA1阴性CM - AVM综合征的儿童病例,该儿童的EPHB4基因发生了新发错义突变,EPHB4是血管生成所必需的跨膜酪氨酸激酶受体。已证明EPHB4基因的失活突变会上调丝裂原活化蛋白激酶途径和雷帕霉素复合物1的哺乳动物靶点,这可能有助于血管畸形的发展。